Biocryst Pharmaceuticals Inc Investor Event Transcript, Nov 18, 2026
Biocryst Pharmaceuticals Inc (BCRX)
BioCryst expects its guidance of $625 to $645 million for this year to finish at the upper end of that range. Pivotal data covering both 12-month and 6-month results are due to read out in Q3 next year. An update on the Netherton syndrome product is expected within the next few weeks, by the end of this year. AI summary
Conference Transcript - BCRX 2026-11-18
Maury Raycroft, Analyst — Jefferies
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Charlie Gehr, the CEO of BioChrist. Charlie's going to start off with a presentation and go through the company and where they're at commercially and with some of the pipeline programs, and then we'll go into a Q&A at the end. And so, without further ado, I'll turn it over to Charlie.
Charlie Gayer, CEO
Great. Thanks, Maury, and thanks to the Jeffries team for inviting us this year. We always enjoy this conference in London. Before I get started, I will be making some forward-looking statements. Those statements have risks. You can read about them in our presentation on our website, and we'll also refer to some non-GAAP financial measures. I thought this year we would do an old school stand-up presentation just because there's a lot going on in the HAE marketplace right now, and we wanted to give you our full perspective on our HAE portfolio, why we have so much confidence in what we're doing today and the future. And it starts with this idea of we do have a portfolio, and the portfolio is growing. So it begins with Orlodeo Capsules that's been on the market since late 2020, and we have seen over this time that... Oral-Adeo is about much more than just convenience. Patients actually get the patients who remain on get injectable-like efficacy, and I'll show you some more of that information in a minute. So we have really strong patient retention, strong physician and patient preference. Recently, we've launched Oral-Adeo pellets, starting with kids aged 2 to 11. It's the first targeted oral prophy product for that age group. And as you can imagine, for kids to have an oral is so critical, and we see the potential of really changing how children grow up with HAE now that they have an oral option. And then recently, we got oralideal pellets also approved for the 12 and up population with 150 milligrams, and we're excited about introducing that to physicians currently and patients very shortly. And then coming next year, top-line data for Novenovar, which we believe could be a transformative It's an innovative product for this marketplace with the first product to have every three- and six-month injectable dosing. The type of efficacy we've seen in Phase 2 is already very strong, so 90-plus percent reduction versus baseline with very durable response at both three- and six-month dosing. And as a calocrine inhibitor, it's a known, just like Orlodeo, it's a known mechanism that physicians and patients are very, very familiar with. So the HAE marketplace is still growing after all the new product introductions. We see the prophylaxis segment being around 8,000 patients today, roughly 5,000 patients on injectable products, another 3,000 on oral, or not quite 3,000 yet, but we see over time growing to 5,000 plus injectable, 3,000 plus oral. By the middle of the 2030s, around 10,000 patients. Yeah, on prophylaxis. All right, so let's kind of address the elephant in the room here, which is there's another oral prophylaxis coming and great results for that product. And so there's kind of a myth out there that for Orlodeo, patients are just taking it today because it's convenient, but it's not very effective. And what I'd like to show you is why we feel so strongly based on our clinical data and real-world evidence that the reality is the patients who stay on Orlodeo get really good efficacy, and that's why they stay on. If they don't, they move on to one of the other options. And this reality is based in the over 1,600 patients in the U.S. that we have on therapy, over 1,500 U.S. prescribers. This year that's been growing by over 60 prescribers per quarter. So still strong growth as more and more doctors get familiar with the Oralodeo story and our data. So it starts with the clinical data. Going back to our APEX-2 study, the patients who started on 150 milligrams, just over 50% of them made it to two years of therapy. And that just over 50% had a 91% reduction in attacks. And so when we started seeing this information, sharing it with physicians, it really changed the idea of Orlodeo as a very effective drug, not just a convenient drug. And then what we see in the real world is, in that first year, about 60% of patients make it to 12 months. And the number of reasons they drop off is they're not getting the efficacy that they were looking for, so that's expected. But once they reach 12 months, the retention is very strong. Thank you. We have launched Oralodeo in a sole source specialty pharmacy, and one of the reasons that we did this is to collect real-world evidence with patients over time. And this has allowed us to build a database of literally hundreds, now over 1,000 patients of evidence, and we've been presenting and publishing this. And what you see here is evidence from classic type 1 and 2, HAE, as well as patients with C1 normal, where patients are reporting for type 1 and 2 getting down to about a third of an attack per month, which is a very competitive attack rate if you look at clinical data from other products. And then the C1 normal patients, which classically had been a very underserved population, they have tremendous real-world success and are getting down from three to four attacks a month down below one attack per month, those that find oral aid to be effective for treating their attacks. And then having this specialty pharmacy allows us, this is another thing that gives us great confidence, is we look at this all the time. So this is a look of roughly the last 90 days, or sorry, 180 days of. HAE patients with type 1 and type 2 HAE who are on Oral Adeo, and they report, 44% of them report being attack-free over that last six months, which, again, we believe is a very competitive attack-free rate. About 70% of them report having two or fewer attacks, and a thing about attacks in the real world is once a patient's on prophylaxis, those attacks tend to be less severe, and so in the end, a patient's decision about control is based on how many attacks they have, but also how manageable are the attacks, and those patients who stay on Orlodeo report a low level of attacks and that the attacks are very manageable. And that leads to, as you would expect, a high level of satisfaction when we survey our patients. And what they say is, what would cause them to switch? Well, if they get some combination of much better efficacy, a better tolerability profile, side effects, and also, importantly, whether they have, they think a lot about the service model, their access to reimbursement, All of which they get with Orlodeo and with our patient services. Then another thing that we do over time that gives us great confidence is every year we do a large survey, not with just a few doctors or just a few patients, but we do a big conjoint analysis with 100 patients, 175 HAA treaters, and 50 payers to survey not just the current market and their views on current products, but everything that's coming in the future. And we always put in front of the treaters and the patients the best possible profile for future products, whether it be Nevenibart, Decryctiband, gene editing, all of that. We show the best possible profile and then run it through a market simulation that we've been doing now since prior to launch that's been very predictive of the trajectory of Orlodeo. And this constantly shows what I'm describing, that the patients who are doing well expect to stay on therapy. The physicians expect them to stay on therapy. So in the future, we expect Orlodeo to continue to grow. With additional competition, that growth may slow down, but it's going to plateau. It's not going to decrease. As I said, the work that we've done has been highly predictive. Back in 2020, we predicted that in 2025, we would sell just over $500 million, and that's what ended up happening. And so our repeated use of this method gives us great confidence in the future. Sorry, one other point just to mention here is that our guidance for this year, $625 to $645 million, at this point, six weeks or so from the end of the year, we expect to end in the upper end of that guidance. Just a point on payer mix, too. This has been very consistent since the launch of Orlodeo. About 60% of the patients are commercial, about a quarter Medicare, the rest mostly Medicaid and a few other government payers. We've been making steady improvements in payment rate, getting close to 85% overall. And just to put it in context, at this point, a percentage point improvement equals about $10 million of annualized revenue. I mentioned the sole source pharmacy, just in terms of how we go to market. That's been a critical piece. For gathering that long-term evidence, but it also gives us very fast near-term evidence. So it's stuff that our sales force uses to act quickly with customers, and then the service level that they provide has been critical, and we get really high marks from patients and HCPs in terms of level of satisfaction with the pharmacy and with our overall patient services and power patient services. And then we have a 40-person sales force in eight regions out there. When we launch Nevenobart in a couple of years, that will stay the same. And so this is a thing with our commercialization of our HAE portfolio. We don't need to increase costs in the future as the portfolio grows. We've already got a very skilled team covering the market, and they are excited about the pediatrics indication today and extremely excited about Nevenobart coming in in the not-so-distant future. So in terms of pediatrics, the uptake of this in the first few months has been stronger than we expected, and maybe this goes back to our APEX-P data where we saw patients getting down to a median monthly attack rate of zero attacks, no AEs causing discontinuations in that study. And the pediatric marketplace is underserved, underdeveloped. We've identified about 500 patients in claims, but if the epidemiology is the same as adults, it should be more like 1,200. And in the early days, we are seeing about a third of patients coming to Oralodeo pellets, switching from other prophy. About a third are coming to prophy from acute-only therapy, and then the other third are new to HAE therapy. And we think an oral option here gives kids with HAE a chance to grow up very differently than their parents or their grandparents did. They can grow up with very few attacks, and that can have a benefit, and we've actually published on this, there's benefit in terms of being able to go to school, healthcare resource use, but you can imagine kind of the psychological benefit, too, for families and for kids of feeling that freedom, feeling less fear, and that can have a long-term benefit for kids' lives, and so we see this as an opportunity for transforming how HAE is treated. Novenibart, again, very excited about what we're seeing here in the Phase II data with excellent reduction at both the three- and the six-month dosing levels. We expect a label with both doses and the flexibility to choose one or the other. It's the same amount of Novenibart that a patient will take in a year, but they'll either take one two-milliliter auto-injector every three months or two every six months. And so that reduction in dosing burden with a mechanism of calocrine inhibition that they know, with a very low level of injection site pain because of the formulation, physicians and patients are very excited about this coming. That three-month dosing really captures their attention. The addition of the six-month really encourages the potential future switch, and so we're excited to launch this in a couple of years. So what do we see going forward for our HAE portfolio? 625 to 645 million this year will come in at the upper end of that guidance. On top of a cost base for BioCrystal, it's actually been coming down. So we've already lowered our OPEX guidance for the year once. We lowered the bottom end at our Q3 earnings to $415 to $425 million. As the impact of the closure of our discovery facilities is fully realized in 2027, we actually expect that OPEX to come down further. So as we think about our current portfolio going forward, OPEX will grow very little, and the revenue will continue to grow. The $1.4 billion to $2 billion of portfolio that we put in there in the mid-30s, that comes from... Analyst consensus. That's the range of analyst views on our portfolio. And we put that out there. We've not put a specific guidance for our portfolio, but the range seems reasonable. We think we could probably do better than 1.4. But all of this on a very stable, low-cost basis gives us an amazing amount of operating leverage, which we plan to use to build our portfolio of other rare disease assets. Both products have IP protection out to the early 2040s, so there's a long period of cash generation in this portfolio. Won't go through all of this, but mainly just to point out, we ended Q3 with a very strong cash position, $376 million. You can see the gap and non-gap operating profit continues to get stronger. It's getting stronger every quarter, and as we go into 2027, we expect that trend to continue. And then finally, our overall portfolio, I've talked about HAE, talked about NoveneBark coming with pivotal data reading out in Q3 of next year for both the 12-month and 6-month results. And then we're excited to report out on our Netherton syndrome product by the end of this year, just in the next few weeks. And that will tell us whether we think we have a product that can go forward in this very serious, rare skin condition where there are currently no approved therapies. And so we look forward to near-term updates on that program. And Maury, with that, I'll take your questions in the last few minutes. Okay.
Maury Raycroft, Analyst — Jefferies
Sounds good. Thanks, Charlie. Maybe just going back to one of the earlier slides where you had the 30 percentage. It could be 30% of the appropriate opportunity. Did you test that, test the respondents with a profile where Decryptive was not on the market? And what did that look like?
Charlie Gayer, CEO
Yeah, so more questions around the... You know, the annual work that we do, how we test future competitors, and for Decryctibent, we just did this survey again this summer, so right before the Decryctibent data came out, the profile that we had was actually, of course, one pill once a day, no side effects, and slightly better efficacy than they actually achieved. They had a great result, but we always like to handicap ourselves as much as possible. And so we think the data that we have from the summer is very representative of what the market thinks and how the market will act when Decryctimate comes out.
Maury Raycroft, Analyst — Jefferies
And so I guess the question is, did you test it? Like, what was the baseline? So if you're going to 30%, where are you at right now? In that survey?
Charlie Gayer, CEO
Oh, in terms of market share?
Maury Raycroft, Analyst — Jefferies
Yeah.
Charlie Gayer, CEO
So Orlodeo, across not just in prophy, but across all treated patients, has about 22%, 23% market share at this point. And so we see that continuing to grow into about the mid-20% and then holding more or less flat.
Maury Raycroft, Analyst — Jefferies
And can you contextualize the 30% then? Is that, are you, from where you're at currently, and what kind of a reduction does that look like if Decryptivant's on the market?
Charlie Gayer, CEO
Not so much a reduction, Maury. It's more of a plateauing, right? So what we expect is that when Decryptivant comes out, we will still get new patient prescriptions because of all the experience the marketplace has with Orlodeo. Um, but they will too. It's a great product, right? And so we won't get quite as many new prescriptions as before, but the patients who are doing really well in Orlodeo are going to stick. So we basically see ourselves plateauing. We'll still be growing in the pediatric part of the market, but, but overall probably a plateauing.
Maury Raycroft, Analyst — Jefferies
Got it. And same thing with, uh, with Nevenobard, Where does the opportunity go once Inventobart's on the market, and what does that share look like?
Charlie Gayer, CEO
I mean, the biggest opportunity is the 5,000-plus patients who are on injectable, and like I mentioned, the profile, there have been some recent advances in injectable therapy, generally moving from every two weeks to every four weeks for patients, and some patients like that. But what we're seeing is it is not, unless patients are having trouble with efficacy, it's not very motivating to move. But when they see a three, every three-month dosing and every six-month dosing. The physicians and the patients see a lot of switching happening. So we think that's our biggest segment. And then, of course, with a portfolio, if you're not doing well in Orlodeo, you want to switch, we have the opportunity to catch a lot of those patients with Nevenobart in the future. So we see those as our two biggest opportunities.
Maury Raycroft, Analyst — Jefferies
Is there anything else in the Phase 3 readout from third quarter next year that would cause people to switch to Nevenobart that you're going to be focused on, besides the convenience factor?
Charlie Gayer, CEO
Yeah, I think, well, it's the convenience, it's competitive efficacy, which we fully expect based on our phase two result. And it is reports of, you know, AEs. We expect low AEs, particularly injection site pain. The market leader today, and we expect in the future to be TaxIro when Nevenobart launches, same mechanism, but painful injections because of the inclusion of citric acid. So Novenobart has a different formulation. It'll be launched in auto-injectors, and that extra benefit is something that's meaningful to patients as they think about switching.
Maury Raycroft, Analyst — Jefferies
Got it. And with Decryctiband launching, could there be any issues on the pricing or payer front if a patient's on Decryctiband, they're having fewer breakthrough attacks, so maybe it's less expensive for that patient overall? I guess, how could that play out from a pricing payer perspective?
Charlie Gayer, CEO
I think the way you describe that is what we believe is a fallacy. The patients on Orlodeo aren't going to be having more attacks. The ones that stay on are going to be having a competitive low rate of attacks, and we have the evidence to show that to payers. It's been tremendously powerful so far in getting patients paid at this point. The other thing is that Orlodeo is well-established with payers, and then we're going to have a portfolio. So we feel good about our overall portfolio relative to payers, and look, I think what you'll see is that we and others are going to price our products based on the value that it's providing to patients, and all of these therapies have provided tremendous value to AGE patients.
Maury Raycroft, Analyst — Jefferies
And so the majority of the patients that you anticipate staying on Orlodeo, it's going to fall in that 44% group that are attack-free.
Charlie Gayer, CEO
Yeah, well, it's the patients, you know, 44% of them are attack-free, very low level of attacks for the others, very low life impact of those attacks. That's who's staying on today. That's who will stay on in the future.
Maury Raycroft, Analyst — Jefferies
Got it. And for the Netherton update, anything additional on higher setting expectations there and maybe talk about next steps based on the results at EC?
Charlie Gayer, CEO
Yeah, so we'll be reporting on up to 12 patients in Part 4 of our study. What we'll be looking for the primary endpoint, basically, is the IASI score, so it's similar to the EZ score in atopic dermatitis, and what we're hearing from physicians from KOLs is that because there are no therapies out there, a meaningful mean reduction across the populations would be about 25%, so we'll be looking at that, and then we'll be looking at responder rate, so if there's a smaller percentage, You know, maybe a third, maybe half of patients in that group who are doing really well, those are the kind of things that are going to tell us what to do at the next stage. So we'll be looking forward to do we go to a pivotal study, do we do more dose exploration if we think that we have a drug. Got it. Okay.
Maury Raycroft, Analyst — Jefferies
And in your recent earnings update, you guys announced a new scientific advisory board in place. What specifically is their mandate around external innovation? And as the business becomes more profitable, has your BDE appetite changed in terms of the stage, size, or type of assets that you want to license?
Charlie Gayer, CEO
Yeah, our SAB, we're thrilled that they joined us, and they joined us. This is not a figurehead kind of advisory board. This is a working advisory board. And so there are advisors who are working with us on a weekly basis as we think about our BD efforts, working with Sandeep and our BD team on this. And so we're looking at a lot of assets, a lot of rare disease areas. Our appetite for what we can do, of course, can grow as our profitability grows, as our cash position grows. But right now we feel that we're well positioned to bring in new products. We want to bring in things clinical stage, and we want to create a balanced pipeline. We've got a great rare disease asset late stage. We've got a potential one early stage, and so we want to start filling in the middle so that we have a consistent pipeline. Got it. Okay.
Maury Raycroft, Analyst — Jefferies
Thanks so much, Charlie.
Charlie Gayer, CEO
Great. Thanks, Murray.